| Overview |
| bs-1158R-PE-Cy5.5 |
| AGEs Polyclonal Antibody, PE-Cy5.5 Conjugated |
| WB, FCM |
| Reacts with BSA-AGE. |
| Human, Mouse, Rat |
| Specifications |
| PE-Cy5.5 |
| Rabbit |
| AGEs |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 280717 |
| P02769 |
| Secreted |
| Advanced Glycation End products; Serum albumin; BSA; ALB |
| Advanced Glycation End products (AGEs) are the result of a chain of chemical reactions after an initial glycation reaction. The intermediate products are known, variously, as Amadori, Schiff base and Maillard products, named after the researchers who first described them. (The literature is inconsistent in applying these terms. For example, Maillard reaction products are sometimes considered intermediates and sometimes end products.) Side products generated in intermediate steps may be oxidizing agents (such as hydrogen peroxide), or not (such as beta amyloid proteins). "Glycosylation" is sometimes used for "glycation" in the literature, usually as 'non-enzymatic glycosylation. The AGE-modified BSA was produced by reacting BSA with glycolaldehyde under sterile conditions followed by extensive dialysis and purification steps. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz